KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity (2018 - 2026)

Castle Biosciences' Common Equity history spans 8 years, with the latest figure at $470.9 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 3.3% to $470.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $470.9 million, a 3.3% increase, with the full-year FY2025 number at $470.9 million, up 3.3% from a year prior.
  • Common Equity hit $470.9 million in Q4 2025 for Castle Biosciences, up from $467.0 million in the prior quarter.
  • Over the last five years, Common Equity for CSTL hit a ceiling of $470.9 million in Q4 2025 and a floor of $378.8 million in Q2 2023.
  • Historically, Common Equity has averaged $419.3 million across 5 years, with a median of $413.8 million in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 376.05% in 2021 and later fell 10.17% in 2023.
  • Tracing CSTL's Common Equity over 5 years: stood at $411.7 million in 2021, then fell by 3.06% to $399.2 million in 2022, then dropped by 1.97% to $391.3 million in 2023, then grew by 16.5% to $455.8 million in 2024, then rose by 3.3% to $470.9 million in 2025.
  • Business Quant data shows Common Equity for CSTL at $470.9 million in Q4 2025, $467.0 million in Q3 2025, and $455.4 million in Q2 2025.